NO20072036L - Syklisk aminderivat eller salt av dette - Google Patents

Syklisk aminderivat eller salt av dette

Info

Publication number
NO20072036L
NO20072036L NO20072036A NO20072036A NO20072036L NO 20072036 L NO20072036 L NO 20072036L NO 20072036 A NO20072036 A NO 20072036A NO 20072036 A NO20072036 A NO 20072036A NO 20072036 L NO20072036 L NO 20072036L
Authority
NO
Norway
Prior art keywords
salt
amine derivative
hydro
disease
derivative
Prior art date
Application number
NO20072036A
Other languages
English (en)
Norwegian (no)
Inventor
Satoshi Hayashibe
Takatoshi Kanayama
Junya Ohmori
Takahiko Tobe
Kyoichi Maeno
Yoshitsugu Shitaka
Jotarou Suzuki
Shigeki Kawabata
Nobuyuki Shiraishi
Shingo Yamasaki
Daisuke Suzuki
Hiroaki Hoshii
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of NO20072036L publication Critical patent/NO20072036L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/42—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having amino groups or hydroxy groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20072036A 2004-09-21 2007-04-20 Syklisk aminderivat eller salt av dette NO20072036L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004274105 2004-09-21
PCT/JP2005/017272 WO2006033318A1 (ja) 2004-09-21 2005-09-20 環状アミン誘導体又はその塩

Publications (1)

Publication Number Publication Date
NO20072036L true NO20072036L (no) 2007-05-23

Family

ID=36090077

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072036A NO20072036L (no) 2004-09-21 2007-04-20 Syklisk aminderivat eller salt av dette

Country Status (15)

Country Link
US (1) US20070197594A1 (cs)
EP (1) EP1795524A4 (cs)
JP (1) JP4748320B2 (cs)
KR (1) KR20070064437A (cs)
CN (1) CN101023055B (cs)
AU (1) AU2005285878B2 (cs)
BR (1) BRPI0515525A (cs)
CA (1) CA2580980C (cs)
IL (1) IL181897A (cs)
MX (1) MX2007003337A (cs)
NO (1) NO20072036L (cs)
RU (1) RU2347776C2 (cs)
TW (1) TW200621677A (cs)
WO (1) WO2006033318A1 (cs)
ZA (1) ZA200702333B (cs)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200900103B (en) * 2006-07-18 2010-03-31 Astellas Pharma Inc Aminoindane derivative or salt thereof
US7786139B2 (en) * 2006-11-21 2010-08-31 Omeros Corporation PDE10 inhibitors and related compositions and methods
EP2083819B1 (en) * 2006-11-21 2017-02-22 Omeros Corporation Pde10 inhibitors and related compositions and methods
PT2221296E (pt) * 2007-11-28 2012-11-23 Astellas Pharma Inc Composto de indano fundido
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8546377B2 (en) * 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
SG2014014328A (en) 2009-05-22 2014-07-30 Abbvie Inc Modulators of 5-ht receptors and methods of use thereof
SG183111A1 (en) 2010-02-16 2012-09-27 Pfizer (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
JP5996528B2 (ja) 2010-05-21 2016-09-21 アッヴィ・インコーポレイテッド ５−ｈｔ受容体調節物質およびその使用方法
AR092924A1 (es) 2012-10-09 2015-05-06 Sanofi Sa Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
WO2018230776A1 (ko) * 2017-06-16 2018-12-20 주식회사 코팜 프테로신 화합물 및 이의 유도체를 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
KR102085358B1 (ko) * 2017-06-21 2020-03-05 고려대학교 산학협력단 프테로신 화합물 및 이의 유도체를 유효성분으로 포함하는 퇴행성 뇌질환 예방 또는 치료용 조성물
TWI812692B (zh) 2018-03-30 2023-08-21 日商東麗股份有限公司 環狀胺衍生物或其藥理學上可容許之鹽之用途
CN110357339B (zh) * 2019-08-14 2021-08-31 盛隆资源再生（无锡）有限公司 一种利用高氟高氨氮废水连续生产氟化钠的方法
IT201900017330A1 (it) * 2019-09-26 2021-03-26 Isagro Spa Processo per la preparazione di (r)-4-amminoindani e corrispondenti ammidi.
US20230348376A1 (en) * 2020-09-15 2023-11-02 Teijin Pharma Limited Vitamin d derivative having cyclic amine in side chain

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470055A1 (de) * 1963-12-07 1969-07-17 Merck Ag E Verfahren zur Herstellung von Piperidinderivaten
CH647235A5 (de) * 1980-02-13 1985-01-15 Sandoz Ag 4-(2,2-dialkylindan-1-yliden)piperidin derivate, ihre herstellung und verwendung.
IE55972B1 (en) * 1982-10-07 1991-03-13 Kefalas As Phenylindene derivatives,acid addition salts thereof,and methods of preparation
ES2059602T3 (es) * 1989-04-14 1994-11-16 Merz & Co Gmbh & Co Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral.
US5703239A (en) * 1995-06-02 1997-12-30 Bristol-Myers Squibb Company Indanylpiperidines as melatonergic agents
CA2220649C (en) * 1996-12-03 2007-02-13 F. Hoffmann-La Roche Ag 4-hydroxy-piperidine derivatives
KR100630506B1 (ko) * 1997-06-30 2006-09-29 메르츠 파마 게엠베하 운트 코. 카가아 Ｎｍｄａ 수용체 길항물질로서의 1-아미노-알킬시클로헥산 화합물, 이를 함유하는 제약학적 조성물 및 이것으로 치료하는 방법
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
WO2001009120A1 (en) * 1999-07-28 2001-02-08 Ortho-Mcneil Pharmaceutical, Inc. Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
DE10050236A1 (de) * 2000-10-11 2002-04-25 Merck Patent Gmbh Verwendung bestimmter Substanzen, die an den Sigma-Rezeptor binden, zur Behandlung von Sarkomen und Karzinomen
CA2452596C (en) * 2001-07-05 2010-12-21 Takeda Chemical Industries, Ltd. Benzo-fused 5-membered heterocyclic compounds, their production and use
JP4357802B2 (ja) * 2001-07-05 2009-11-04 武田薬品工業株式会社 ベンゼン環縮合５員複素環式化合物、その製造法および用途

Also Published As

Publication number Publication date
TWI337988B (cs) 2011-03-01
CA2580980A1 (en) 2006-03-30
IL181897A (en) 2012-05-31
TW200621677A (en) 2006-07-01
AU2005285878B2 (en) 2011-06-30
ZA200702333B (en) 2009-05-27
BRPI0515525A (pt) 2008-08-05
JP4748320B2 (ja) 2011-08-17
CN101023055B (zh) 2010-10-06
CN101023055A (zh) 2007-08-22
WO2006033318A1 (ja) 2006-03-30
RU2347776C2 (ru) 2009-02-27
US20070197594A1 (en) 2007-08-23
CA2580980C (en) 2011-05-03
KR20070064437A (ko) 2007-06-20
JPWO2006033318A1 (ja) 2008-05-15
MX2007003337A (es) 2007-05-21
RU2007115093A (ru) 2008-11-10
IL181897A0 (en) 2007-07-04
AU2005285878A1 (en) 2006-03-30
EP1795524A1 (en) 2007-06-13
EP1795524A4 (en) 2009-08-05

Similar Documents

Publication Publication Date Title
NO20072036L (no) Syklisk aminderivat eller salt av dette
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
CY1113561T1 (el) (2s,3r)-ν-(2-((3-πυριδινυλ)μεθυλ)-1-αζαδικυκλο[2.2.2]οκτ-3-υλ)βενζοφουραν-2-καρβοξαμιδιο, νεες μορφες αλατων και μεθοδοι χρησεως αυτων
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20060167L (no) Benzamidderivat eller salt derav
NO20073876L (no) Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20064577L (no) Tetrahydronaftyndin-derivater nyttige som histamin H3 reseptorligander
NO20092138L (no) Forbindelser og sammensetninger som proteinkinase inhibitorer
NO20071300L (no) Trifluormetylsubstituerte benzamider som kinaseinhibitorer.
NO20080484L (no) Niacin-reseptorantagonister, preparater inneholdende slike forbindelser og behandlingsmetoder
BR0109235A (pt) Derivados do ácido carboxìlico como antagonistas ip
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
DK1546127T3 (da) Nye pyrimidinamidderivater og anvendelse deraf
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
BR0316950A (pt) Derivados de indazol como antagonistas de crf
NO20070067L (no) Pyrrolopyridinderivater
BRPI0515851A (pt) composto de pirimidona
BRPI0415631A (pt) derivados de tetrazol e métodos de tratamento de distúrbios metabólico-relacionados dos mesmos
NO20080669L (no) Acetylenpiperaziner som metabotrofiske glutamatreseptorantagonister
NO20062824L (no) 1,3-Difenylprop-2-en-1-on-avledete forbindelser, fremgangsmater for fremstilling derav, samt anvendelse av samme
Yu et al. Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters
NO20080671L (no) Bisykliske piperaziner som metabotrofiske glutamatreseptorantagonister
BRPI0508825A (pt) compostos derivados de benzil (ideno)-lactama, suas composições farmacêuticas e processos para suas preparações

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application